Don’t Forget About the Flu: Identifying, Treating, and Protecting High-Risk Patients
Friday, October 22, 2021
12:00 -1:00 PM ET
Faculty Presenter
James S. Lewis II, PharmD, FIDSA
Infectious Diseases Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Departments of Pharmacy and Infectious Diseases
Oregon Health & Science University
Portland, OR
This activity is jointly provided by Educational Review Systems, Inc and Paradigm Medical Communications, LLC.
Disclosure of Financial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Target Audience
This activity has been designed to address the educational needs of community, health-system, and hospital pharmacists. It may also benefit other clinicians involved in the care of patients with, or at risk for, influenza virus infection.
Statement of Need
Many US states have expanded the role of pharmacists in influenza, which remains a persistent threat. Pharmacists are essential to influenza prevention and preparedness efforts, and their involvement in influenza care is consistently shown to improve outcomes. This evidence-based program will provide pharmacists with updates on best practices for identifying influenza and guiding the use of antiviral therapy, which is currently underused, even among high-risk patients who are susceptible to worse outcomes. The program will acquaint pharmacists with shifts in influenza diagnosis and care that have been prompted by the emergence of COVID-19, and the availability of a first-in-class oral antiviral agent, for which data, indications, and formulations continue to accumulate, warranting immediate practice changes in both treatment and prophylaxis.
Learning Objectives
Upon completion of this activity, participants should be able to:
· Identify appropriate candidates for antiviral therapy based on risk for influenza-related complications, in accordance with current guideline recommendations
· Differentially diagnose influenza based on clinical presentation and accurate interpretation of appropriate diagnostic tests when necessary
· Recommend individualized antiviral treatment plans for patients with influenza based on current data and unique agent characteristics
· Advise on influenza prophylaxis based on evidence and in accordance with guideline recommendations
Agenda
- · Welcome and Introduction
- · Pharmacy and Flu: What’s New?
- · Pharmacy and Flu: What’s Not New?
- · Who Should Receive Antiviral Therapy?
- · Which Antiviral Therapy Should I Choose?
- · Q&A
Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.0 contact hours (0.10 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-21-293-L01-P; 0761-9999-21-293-L01-T
This is a knowledge-based activity.
How to Receive Your CPE Credit
To receive a CPE certificate of participation, you must:
· Attend the live activity
· Complete the activity postsurvey, evaluation, and request for credit form
A certificate of participation will be issued 1 to 2 weeks following the meeting.
For questions regarding CPE credit, contact the Paradigm CME Department at cme@paradigmmc.com or (845) 398-5949.
There is no fee required for participation in this activity.
Disclosures
In accordance with ACPE requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.
Faculty
Jason E. Bowling, MD
Advisor: Eli Lilly and Company
James S. Lewis II, PharmD, FIDSA
Consulting Fees: Cidara Therapeutics, Inc; Merck & Co, Inc; Selux Diagnostics, Inc
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Educational Review Systems, Inc staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
Educational Review Systems, Inc and Paradigm Medical Communications, LLC have implemented a system to resolve conflicts of interest for each CPE activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CPE content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACPE guidelines.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CPE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Educational Review Systems, Inc or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As accredited providers, Educational Review Systems, Inc and Paradigm Medical Communications, LLC must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Educational Review Systems, Inc or Paradigm Medical Communications, LLC.
© 2021 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.
